CMG Pharmaceutical Faces Delisting Risk Over Minimum Share Price Requirement
Bitget2026/10/30 10:42- CMG Pharmaceutical faces delisting unless common shares close at 1,000 won or higher for 45 consecutive trading days within a 90-trading-day period.
- The stock was designated for administrative supervision on Aug. 13, 2026, following 30 consecutive trading days with closing prices below 1,000 won.
- As of Oct. 29, 36 trading days had elapsed since designation; shares had met the price threshold for four consecutive trading days.
- A closing price below 1,000 won from the 46th trading day following designation could trigger delisting under Kosdaq listing rules.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Indonesian Rupiah: External headwinds and MSCI risks – OCBC
Taiwan Dollar: Strong fundamentals but near-term pressure – Commerzbank

Hassett Downplays AI Debt Risk: The Industry Has Sufficient Funds, No Risk of Broad Sell-Off
Kevin Hassett, Director of the White House National Economic Council, stated that the recent substantial decline in technology stocks does not indicate a comprehensive sell-off risk for the AI industry. He acknowledged that some enterprises are indeed burdened with significant debt, which warrants attention. However, he also pointed out that there are many financially strong companies within the industry that hold both equity and debt in related firms; these companies may be poised to acquire or provide funding support when opportunities arise.
